ScholarIQanswers from OpenAlex & ORCID
Hong Jian
ResearcherPublications, citations & collaboration network
Hong Jian is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hong Jian have?
ScholarIQindexed works
Hong Jian has 61 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hong Jian have?
ScholarIQcitation count
Hong Jian has 2,073 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hong Jian?
ScholarIQh-index
Hong Jian has an h-index of 22 in OpenAlex.
What is the i10-index of Hong Jian?
ScholarIQi10-index
Hong Jian has an i10-index of 31 in OpenAlex.
What is the ORCID of Hong Jian?
ScholarIQorcid
The ORCID for Hong Jian is on the source record.
What is the OpenAlex record for Hong Jian?
ScholarIQopenalex
The OpenAlex for Hong Jian is on the source record.
What are the most-cited papers on Hong Jian?
ScholarIQmost cited works
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations
Shun Lü, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhixiang Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lü, Yanping Hu, Liyan Jiang, Qiming Wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wan-cheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Weng Jie, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Changan Sun, Hongying Wei, Chuan Li, Siraj M. Ali, Vincent A. Miller, Qiong Wu
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Shun Lü, Lin Wu, Hong Jian, Ying Chen, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Meili Sun, Liang Han, Liyun Miao, Cuimin Ding, Jiuwei Cui, Baolan Li, Yueyin Pan, Xingya Li, Feng Ye, Anwen Liu, Ke Wang, Shundong Cang, Hui Zhou, Xing Sun, David Ferry, Yong Lin, Shuyan Wang, Wen Zhang, Chengli Zhang
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Shun Lü, Lin Wu, Hong Jian, Ying Cheng, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Liang Han, Meili Sun, Liyun Miao, Cuimin Ding, Jiuwei Cui, Ke Wang, Baolan Li, Xingya Li, Feng Ye, Anwen Liu, Yueyin Pan, Shundong Cang, Hui Zhou, Xing Sun, Yuping Shen, Shuyan Wang, Wen Zhang, Yue He
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
James Chih‐Hsin Yang, D. Ross Camidge, Cheng‐Ta Yang, Jianying Zhou, Renhua Guo, Chao‐Hua Chiu, Gee‐Chen Chang, Her-Shyong Shiah, Yuan Chen, Chin-Chou Wang, David Berz, Wu‐Chou Su, Nong Yang, Ziping Wang, Jian Fang, Jianhua Chen, Petros Nikolinakos, You Lu, Hongming Pan, Ajit Maniam, Lyudmila Bazhenova, Keisuke Shirai, Mohammad Jahanzeb, Maurice Willis, Nehal Masood, N. M. Chowhan, Te‐Chun Hsia, Hong Jian, Shun Lü
Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial
Yi Jiang, Lingshuang Liu, Liping Shen, Zhifen Han, Hong Jian, Jiaxiang Liu, Ling Xu, Hegen Li, Jianhui Tian, Zhu-Jun Mao